The Immunogenicity of a conformationally restricted peptide mimetic of meningococcal lipooligosaccharide

Scandinavian Journal of Immunology

Volumn 62, Issue 4, 2005, Pages 385-392

  Tiwana, H ^a   Clow, K J ^b   Hall, C ^c   Feavers, I M ^b   Charalambous, B M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C22 PEPTIDE NEUTRAVIDIN; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BLOOD GROUP TYPING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; FEMALE; HAPLOTYPE; IMMUNE RESPONSE; IMMUNOGENICITY; MENINGITIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; SPLEEN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MOLECULAR MIMICRY; NEISSERIA MENINGITIDIS; PEPTIDES; PROTEIN CONFORMATION; SPLEEN;

EID: 27644549420     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01671.x     Document Type: Article

References (56)

1. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-508.
2. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2001;20:666-87.
3. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992;165:S49-S52.
4. Adams WG, Deaver KA, Cochi SL et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
5. Campagne G, Garba A, Fabre P et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000;19:144-50.
6. Anderson EL, Bowers T, Mink CM et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62:3391-5.
7. MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA 2000;283:2795-801.
8. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998;280:1685-9.
9. Ahman H, Kayhty H, Lehtonen H, Leroy O, Froeschle J, Eskola J. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr Infect Dis J 1998;17:211-6.
10. Wyle FA, Artenstein MS, Brandt BL et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972;126:514-21.
11. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983;ii:355-7.
12. Vermont CL, Van Dijken HH, Kuipers AJ et al. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect Immun 2003;71:1650-5.
13. de Kleijn ED, de Groot R, Lafeber AB et al. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 2000;19:1141-8.
14. de Kleijn E, van Eijndhoven L, Vermont C et al. Serum bactericidal activity and isotype distribution of antibodies in toddlers and school children after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 2001;20:352-8.
15. Longworth E, Borrow R, Goldblatt D et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002;20:2592-6.
16. Ala'Aldeen DAA, Stevenson P, Griffiths E et al. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design. Infect Immun 1994;62: 2984-90.
17. Martin D, Cadieux N, Hamel J, Brodeur BR. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 1997;185:1173-83.
18. Granoff DM, Moe GR, Giuliani MM et al. A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol 2001; 167:6487-96.
19. Oliver KJ, Reddin KM, Bracegirdle P et al. Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 2002;70:3621-6.
20. Gu XX, Tsai C-M. Preparation, characterisation and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect Immun 1993;61:1873-80.
21. Plested JS, Harris SL, Wright JC et al. Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis 2003;187:1223-34.
22. Verheul AF, Boons GJ, van der Marel GA et al. Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3, 7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect Immun 1991;59:3566-73.
23. Jennings HJ, Johnson KG. The structure of an R-type oligosaccharide core obtained from some lipooligosaccharides of Neisseria meningitidis. Carbohydr Res 1983;121:233-41.
24. Jones DM, Borrow R, Fox AJ, Gray S, Cartwright KA, Poolman JT. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 1992;13:219-24.
25. Preston A, Mandrell RE, Gibson BW, Apicella MA. The lipooligosaccharides of pathogenic gram-negative bacteria. Crit Rev Microbiol 1996;22:139-80.
26. Estabrook M, Baker CJ, Griffiss JM. The immune response of children to meningococcal lipooligosaccharides during disseminated disease is directed towards primarily against two monoclonal antibody-defined epitopes. J Infecti Dis 1993;167:966-70.
27. Plested JS, Makepeace K, Jennings MP et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun 1999;67:5417-26.
28. Charalambous BM, Feavers IM. Peptide mimics elicit antibody responses against the outer-membrane lipooligosaccharide of group B Neisseria meningitidis. FEMS Microbiol Lett 2000;191:45-50.
29. Brett PJ, Tiwana H, Feavers IM, Charalambous BM. Characterisation of oligopeptides that cross-react with carbohydrate specific antibodies by real-time kinetic, in-solution competition ELISA and immunological analyses. J Biol Chem 2002;277:20468-76.
30. Charalambous BM, Evans J, Feavers IM, Maiden MC. Comparative analysis of two meningococcal immunotyping monoclonal antibodies by resonant mirror biosensor and antibody gene sequencing. Clin Diagn Lab Immunol 1999;6:838-43.
31. Scholten RJ, Kuipers B, Valkenburg HA, Dankert J, Zollinger WD, Poolman JT. Lipooligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med 1994;41:236-43.
32. Sasazuki T, Kohno Y, Iwamoto I, Tanimura M, Naito S. Association between an HLA haplotype and low responsiveness to tetanus toxoid in man. Nature 1978;272:359-61.
33. Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983;40:257-64.
34. Borrow R, Carlone GM. Serogroup B and C serum bactericidal assays. In: Pollard AJ, Maiden MCJ, eds. Methods in Molecular Medicine: Meningococcal Vaccines Methods and Protocols. New Jersey: Humana Press Inc., 2002;289-304.
35. Abdillahi H, Poolman JT. Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett 1987;48:367-71.
36. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine 'Folkehelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14:67-79.
37. Beech JT, Bainbridge T, Thompson SJ. Incorporation of cells into an ELISA system enhances antigen-driven lymphokine detection. J Immunol Methods 1997;205:163-8.
38. Lesinski GB, Smithson SL, Srivastava N, Chen D, Widera G, Westerink MA. A DNA vaccine encoding a peptide mimic of Streptococcus pneumoniae serotype 4 capsular polysaccharide induces specific anti-carbohydrate antibodies in Balb/c mice. Vaccine 2001;19:1717-26.
39. Grothaus MC, Srivastava N, Smithson SL et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 2000;18:1253-63.
40. Charalambous BM, Feavers IM. Mimotope vaccines. J Med Microbiol 2001;50:937-9.
41. Cabezas E, Wang M, Parren PW, Stanfield RL, Satterthwait AC. A structure-based approach to a synthetic vaccine for HIV-1. Biochemistry 2000;39:14377-91.
42. Chen X, Scala G, Quinto I et al. Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes. Nat Med 2001;7: 1225-31.
43. Chargelegue D, Obeid OE, Hsu SC et al. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo. J Virol 1998;72:2040-6.
44. Alba MP, Salazar LM, Puentes A, Pinto M, Torres E, Patarroyo ME. 6746 SERA peptide analogues immunogenicity and protective efficacy against malaria is associated with short alpha helix formation: malaria protection associated with peptides alpha helix shortening. Peptides 2003;24:999-1006.
45. Apostolopoulos V, Matsoukas J, Plebanski M, Mavromoustakos T. Applications of peptide mimetics in cancer. Curr Med Chem 2002;9:411-20.
46. Kieber-Emmons T, Luo P, Qiu J et al. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol 1999;17:660-5.
47. Tzitzilonis C, Brett P, Feavers I, Lian LY, Derrick JP, Charalambous BM. Mimotopes of TV meningitidis lipooligosaccharide. 12th IPNC meeting, 2000.
48. Gaubin M, Fanutti C, Mishal Z et al. Processing of filamentous bacteriophage virions in antigen-presenting cells targets both HLA class I and class II peptide loading compartments. DNA Cell Biol 2003;22:11-8.
49. Stevanovic S. Structural basis of immunogenicity. Transpl Immunol 2002;10:133-6.
50. Muller S. Immunisation with peptides. In: Van Regenmortel MHV Muller S, eds. Synthetic Peptides as Antigens. Amsterdam: Elsevier, 1999:133-77.
51. Lauvrak V Berntzen G Heggelund U et al. Selection and characterization of cyclic peptides that bind to a monoclonal antibody against meningococcal L3,7,9 lipopolysaccharides. Scand J Immunol 2004;59:373-84.
52. Green NM. Avidin. Adv Protein Chem 1975;29:85-133.
53. Bruch RC, White HB III. Compositional and structural heterogeneity of avidin glycopeptides. Biochemistry 1982;21:5334-41.
54. Alon R, Bayer EA, Wilchek M. Streptavidin contains an RYD sequence which mimics the RGD receptor domain of fibronectin. Biochem Biophys Res Commun 1990;170:1236-41.
55. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001;70:849-60.
56. Cribbs DH, Ghochikyan A, Vasilevko V et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003;15:505-14.